Objective: Creating an appropriate antithrombotic therapy for patients with atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI) remains a dilemma. Several clinical trials compared the use of a dual antithrombotic therapy (DAT) regimen with a direct oral anticoagulants including (apixaban, dabigatran, edoxaban or rivaroxaban) and a P2Y inhibitor versus a triple antithrombotic therapy (TAT) that includes a vitamin K antagonist plus aspirin and a P2Y inhibitor in patients with AF who have undergone PCI. However, there are no head-to-head trials comparing the DAT regimens to each other. We aimed to compare the efficacy and safety of DAT regimens using a network meta-analysis (NMA) approach.
Design: A systematic review and NMA of randomised clinical trials.
Methods: We conducted a systematic literature review to identify relevant randomised clinical trials and performed a Bayesian NMA for International Society on Thrombosis and Haemostasis (ISTH) major or clinically relevant non-major (CRNM) bleeding, all-cause mortality, stroke, myocardial infarction (MI) and stent thrombosis outcomes. We used NetMetaXL V.1.6.1 and WinBUGS V.1.4.3 for the NMA and estimated the probability of ranking the treatments based on the surface under the cumulative ranking curve.
Results: The comparison between DAT regimens showed no significant difference in the safety or efficacy outcomes. Apixaban regimen was ranked first as the preferred therapy in terms of ISTH major or CRNM bleeding and stroke, with a probability of 52% and 54%, respectively. Rivaroxaban regimen was the preferred therapy in terms of MI and stent thrombosis, with a probability of 34% and 27%, respectively. Dabigatran regimen was ranked first in terms of all-cause mortality, with a probability of 28%.
Conclusion: The DAT regimens are as safe and effective as TAT regimens. However, ranking probabilities for the best option in the selected outcomes can be used to guide the selection among these agents based on different patients' conditions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526290 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2019-036138 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Single Antiplatelet Therapy and Dual Antiplatelet Therapy after Endovascular Therapy in Patients with Lower Extremity Artery Disease.
Ann Vasc Dis
December 2024
Division of Cardiology, Central Japan International Medical Center, Minokamo, Gifu, Japan.
Evidence for antithrombotic therapy after endovascular therapy (EVT) is limited. This retrospective, multicenter, observational study enrolled 732 consecutive patients with lower extremity artery disease who underwent EVT between January 2018 and December 2019. Overall, 570 patients who received single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) were selected and divided into the SAPT (n = 189) and DAPT (n = 381) groups.
View Article and Find Full Text PDFImpact of Antithrombotic Drug Continuation on Postoperative Outcomes in Patients with Carpal Tunnel Syndrome: A Randomised, Open-Label, Parallel Group Trial.
J Hand Surg Asian Pac Vol
December 2024
Department of Human Enhancement and Hand Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Article Synopsis
- The study examined how continuing or stopping antithrombotic drugs affects postoperative outcomes in patients with carpal tunnel syndrome undergoing endoscopic release surgery.
- 65 patients were divided into two groups: those who maintained their antithrombotic therapy and those who suspended it, with various measures of outcomes assessed before and after surgery.
- Results showed that patients who temporarily stopped their antithrombotic medication reported significantly less symptom severity and swelling three months post-surgery, with no complications reported in either group.
Systematic review and meta-analysis of audits measuring antithrombotic therapy within forty-eight hours for ischemic stroke.
J Stroke Cerebrovasc Dis
December 2024
Stroke and Aging Research Group, Department of Medicine, Monash University, Melbourne, Australia. Electronic address:
Article Synopsis
- A meta-analysis showed that 81.1% of patients received antithrombotic therapy within 48 hours of ischemic stroke, indicating general compliance with treatment guidelines.
- There was no significant difference in therapy rates between low- to middle-income countries and high-income countries, nor between older and more recent studies.
- The study concluded that most countries still fall short of the standards set by North America's Get With The Guidelines program for early antiplatelet therapy.
Ischemic Stroke Prevention in Patients Atrial Fibrillation and a Recent Ischemic Stroke, TIA, or Intracranial Hemorrhage; a World Stroke Organisation (WSO) Scientific Statement.
Int J Stroke
December 2024
Division of Neurology, McMaster University, Hamilton, ON, Canada.
Background: Secondary stroke prevention in patients with atrial fibrillation (AF) is one of the fastest growing areas in the field of cerebrovascular diseases. This Scientific statement from the World Stroke Organization Brain & Heart Task Force provides a critical analysis of the strength of current evidence this topic, highlights areas of current controversy, identifies knowledge gaps, and proposes priorities for future research.
Methods: We select topics with the highest clinical relevance and perform a systematic search to answer specific practical questions.
Thromboembolic Events in the Hemodialysis Setting: Understanding Risk Profiles and Cumulative Incidences to Inform Clinical Trial Design.
J Am Heart Assoc
December 2024
Arbor Research Collaborative for Health Ann Arbor MI USA.
Background: People with kidney failure have a high risk of cardiovascular morbidity/death, including thromboembolic events. Factor XIa inhibitors are a new class of anticoagulants in development that may offer antithrombotic benefits with a lower risk of incremental bleeding events than traditional therapies. We investigated major adverse vascular events (MAVEs), a relevant composite outcome for testing novel antithrombotic agents, in a large cohort of patients on hemodialysis, to better understand the key requirements to adequately design a phase 3 trial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!